newsfilter
← Latest News
GlobeNewswire·

DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

IND application for DICE's lead oral IL-17 antagonist, DC-806, cleared by FDA; global Phase 2b clinical trial in patients with moderate-to-severe psoriasis on track to initiate in 1H 2023First participants dosed in Phase